Clinical Trial Update: Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing safety and immunogenicity of an adjuvanted reduced-dose inactivated polio vaccine in infants aged 2, 4, and 6 months.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poliomyelitis

Drugs mentioned

• adjuvanted reduced-dose inactivated polio vaccine

Snippet

Sponsor: Statens Serum Institut | Conditions: Poliomyelitis | Phase 3 | Status: COMPLETED